Immunogenicity and Safety of COVID-19 Vaccine BNT162b2 for Patients with Solid Cancer: A Large Cohort Prospective Study from a Single Institution.

Vincenzo Di NoiaFulvia PimpinelliDavide RennaVittoria BarberiMaria Teresa MaccalliniLudovica GariazzoMartina PontoneAlessandro MontiFlaminia CampoEmanuela TaraborelliMaria Di SantoFabrizio PetroneChiara MandojVirginia FerraresiGianluigi FerrettiPaolo CarliniOrnella Di BellaLaura ContiAntonia Marina La MalfaRaul PelliniDomenico BraccoDiana GiannarelliAldo MorroneFrancesco Cognetti

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)

BNT162b2 assures serologic immunization without clinically significant toxicity in CP. The second dose is needed to reach a satisfactory humoral response.

Keyphrases

coronavirus disease
papillary thyroid
sars cov
immune response
respiratory syndrome coronavirus
squamous cell
oxidative stress
squamous cell carcinoma
childhood cancer